Pintu Kumar DE
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pintu Kumar DE has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Dibya Das
Department of Pharmaceutical Technology, JIS University, Kolkata, India
2 shared publications - Moumita Chowdhury
Guru Nanak Institute of Pharmaceutical Science and Technology, 157/F Nilgunj Road, Panihati, Sodepur, Kolkata-114, West Bengal, India
2 shared publications - Anirbandeep Bose
Adamas University
1 shared publication - Chiranjit Saha
TAAB Biostudy Services, Jadavpur, Kolkata, India
1 shared publication - Dhiman Halder
Department of Pharmaceutical Technology, Bioequivalence Study Centre, Jadavpur University, Kolkata, India
1 shared publication - Gourav Samajdar
Department of Pharmaceutical Technology, JIS University, Kolkata, India
1 shared publication
Latest Publications
- Open Access
- 7 July 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 337-343
IN VIVO PHARMACOKINETICS STUDY OF DICLOFENAC SODIUM LOADED BASELLA ALBA MUCILAGE BASED CARRIER FOR ENHANCEMENT OF ORAL BIOAVAILABILITY
Objective: The present study aims to evaluate the in vivo bioavailability and pharmacokinetics of diclofenac sodium entrapped in a natural polysaccharide, Basella alba mucilage-based carrier. Methods: In this study, mucilage from Basella alba was chemically modified to improve its physicochemical properties and evaluated for its extent of modification by elemental analysis. The Diclofenac sodium-loaded sustained-release hydrogel bead developed from tailored Basella alba mucilage was evaluated for particle size, drug entrapment and Scanning electron microscopy. The resulting beads were used to assess the in vivo pharmacokinetics and bioavailability study. The pharmacokinetics of diclofenac sodium and diclofenac sodium loaded formulation were studied and compared with a marketed formulation of Diclofenac sodium (Subsyde®-CR DRCM capsule) at an equivalent dose in three groups of Wistar albino rats containing six rats in each group. Blood samples were collected via retro-orbital puncture for a period of 24 h. The diclofenac sodium concentration in a plasma sample of rats was detected by HPLC and the pharmacokinetic parameters were analyzed by noncompartmental modeling using PK solver. Results: The elemental analysis and degree of substitution confirmed the chemical modification of Basella alba mucilage. The Basella alba mucilage-based beads showed uniform surface with drug entrapment efficiency of 71.56%±0.85. The pharmacokinetic parameters of raw drug and test formulation showed significant difference (p<0.01), whereas test and marketed formulation appeared similar without any significant difference. The results showed higher mean residence time, increased tmax, and decreased Cmax of drug-loaded beads and marketed formulation than the pure drug. The relative bioavailability of Diclofenac sodium increased from 54.50% to 96.88% by entrapping it in Basella alba mucilage-based bead. Conclusion: Thus, the present work unfolded the potential of Basella alba mucilage as a bioavailability enhancer, advocating its use in developing novel pharmaceutical formulations.
- 7 July 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 337-343
Open AccessIN VIVO PHARMACOKINETICS STUDY OF DICLOFENAC SODIUM LOADED BASELLA ALBA MUCILAGE BASED CARRIER FOR ENHANCEMENT OF ORAL BIOAVAILABILITY
Objective: The present study aims to evaluate the in vivo bioavailability and pharmacokinetics of diclofenac sodium entrapped in a natural polysaccharide, Basella alba mucilage-based carrier. Methods: In this study, mucilage from Basella alba was chemically modified to improve its physicochemical properties and evaluated for its extent of modification by elemental analysis. The Diclofenac sodium-loaded sustained-release hydrogel bead developed from tailored Basella alba mucilage was evaluated for particle size, drug entrapment and Scanning electron microscopy. The resulting beads were used to assess the in vivo pharmacokinetics and bioavailability study. The pharmacokinetics of diclofenac sodium and diclofenac sodium loaded formulation were studied and compared with a marketed formulation of Diclofenac sodium (Subsyde®-CR DRCM capsule) at an equivalent dose in three groups of Wistar albino rats containing six rats in each group. Blood samples were collected via retro-orbital puncture for a period of 24 h. The diclofenac sodium concentration in a plasma sample of rats was detected by HPLC and the pharmacokinetic parameters were analyzed by noncompartmental modeling using PK solver. Results: The elemental analysis and degree of substitution confirmed the chemical modification of Basella alba mucilage. The Basella alba mucilage-based beads showed uniform surface with drug entrapment efficiency of 71.56%±0.85. The pharmacokinetic parameters of raw drug and test formulation showed significant difference (p<0.01), whereas test and marketed formulation appeared similar without any significant difference. The results showed higher mean residence time, increased tmax, and decreased Cmax of drug-loaded beads and marketed formulation than the pure drug. The relative bioavailability of Diclofenac sodium increased from 54.50% to 96.88% by entrapping it in Basella alba mucilage-based bead. Conclusion: Thus, the present work unfolded the potential of Basella alba mucilage as a bioavailability enhancer, advocating its use in developing novel pharmaceutical formulations.
- Open Access
- 7 September 2023
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 106-116
TAILORED BASELLA ALBA MUCILAGE-BASED BIPOLYMERIC HYDROGEL BEADS FOR CONTROLLED RELEASE OF DICLOFENAC SODIUM
Objective: The present investigation aims to convert the underutilized Basella alba mucilage (BAM) into a smart carrier by formulating its bipolymeric hydrogel beads for the controlled release of Diclofenac sodium (DFS). Methods: At first, mucilage from the stem and fruits of Basella alba was extracted, isolated, and evaluated. Basella alba mucilage was chemically modified to its carboxymethyl derivative to improve its physicochemical properties. Single and bipolymeric hydrogel beads of carboxymethylated Basella alba mucilage (CBAM) and Sodium carboxymethyl cellulose (SCMC) were formulated by the Ionotropic gelation method using aluminium chloride (AlCl3) as a cross-linking agent. A four-factor I-optimal response surface design was used to optimize the formulations. Drug and excipient compatibility was studied by Fourier transform infrared spectroscopy (FTIR) and Differential Scanning Calorimetry (DSC) study. Scanning electron microscopy (SEM) was done to reveal the surface morphology. In vitro release of the drug in phosphate buffer (pH 6.8) and acidic buffer (pH 1.2) were compared for all the formulations. The effect of various formulation parameters on the release of the drug was studied, and the best-fitting model for release kinetics was determined. Results: The degree of carboxymethylation was found to be 0.565±0.05. The bipolymeric beads were found to release 14% drug in 2 h in acidic media, minimize the release of the drug in the stomach to avoid the harsh effects of DFS and then provide controlled release in the intestine, releasing 80-90% of the drug in 10 h. The release kinetics followed the Hixon Crowell model, which suggests an erosion of the matrix to release the drug. Conclusion: The bipolymeric hydrogel beads of tailored Basella alba mucilage were found to control the release of Diclofenac sodium.
- 7 September 2023
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 106-116
Open AccessTAILORED BASELLA ALBA MUCILAGE-BASED BIPOLYMERIC HYDROGEL BEADS FOR CONTROLLED RELEASE OF DICLOFENAC SODIUM
Objective: The present investigation aims to convert the underutilized Basella alba mucilage (BAM) into a smart carrier by formulating its bipolymeric hydrogel beads for the controlled release of Diclofenac sodium (DFS). Methods: At first, mucilage from the stem and fruits of Basella alba was extracted, isolated, and evaluated. Basella alba mucilage was chemically modified to its carboxymethyl derivative to improve its physicochemical properties. Single and bipolymeric hydrogel beads of carboxymethylated Basella alba mucilage (CBAM) and Sodium carboxymethyl cellulose (SCMC) were formulated by the Ionotropic gelation method using aluminium chloride (AlCl3) as a cross-linking agent. A four-factor I-optimal response surface design was used to optimize the formulations. Drug and excipient compatibility was studied by Fourier transform infrared spectroscopy (FTIR) and Differential Scanning Calorimetry (DSC) study. Scanning electron microscopy (SEM) was done to reveal the surface morphology. In vitro release of the drug in phosphate buffer (pH 6.8) and acidic buffer (pH 1.2) were compared for all the formulations. The effect of various formulation parameters on the release of the drug was studied, and the best-fitting model for release kinetics was determined. Results: The degree of carboxymethylation was found to be 0.565±0.05. The bipolymeric beads were found to release 14% drug in 2 h in acidic media, minimize the release of the drug in the stomach to avoid the harsh effects of DFS and then provide controlled release in the intestine, releasing 80-90% of the drug in 10 h. The release kinetics followed the Hixon Crowell model, which suggests an erosion of the matrix to release the drug. Conclusion: The bipolymeric hydrogel beads of tailored Basella alba mucilage were found to control the release of Diclofenac sodium.
- Open Access
- 7 March 2023
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 219-227
A STRATEGIC PROCESS DEVELOPMENT AND IN VITRO CYTOTOXICITY ANALYSIS OF PACLITAXEL-LOADED LIPOSOMES
Objective: Liposomes are the controlled-release dosage form that improves the therapeutic efficacy of the drugs, prolongs the duration of action, reduces dosage frequency, and improves patient compliance. Methods: The thin-film hydration method was used to prepare Paclitaxel liposomes. In this process, cholesterol and sodium deoxycholate were used for the formulation, while chloroform and methanol were used as diluents. Percentage (%) drug release study was carried out in phosphate buffer at pH 7.4 in USP apparatus II (Paddle type)Model no VDA-8D, Veego, Mumbai, India. Results: Paclitaxel liposomes of various batches showed a percentage yield ranging from 38 to 84%. It was observed that (Encapsulation efficiency)EE% of Batches B1 to B10 were 0,62.33,59.51,50.21,44.30,82.25,88.95,72.34,77.37 and 70.63 percentage, respectively. Data fitting to the Peppas, Higuchi, 1st-order, and zero-order models was used to examine the optimized liposome (B7) release kinetic mechanism. Data comparison was done using the correlation coefficient (R2). Zero-order had an observed correlation coefficient (R2) of 0.9988, which was greater than that for other models. Therefore, it was clear that the medication was released from the formulation after the zero-order release. Conclusion: The prepared liposomes were subjected to various evaluation parameters like SEM, zeta potential, particle size analysis, drug release study, etc. Data showed that an increased concentration of cholesterol increases the drug release from liposomes. Microscopic images of the B7 batch revealed that liposomes are spherical and have regular surfaces. Formulation B7 shows good results and can be considered an optimized batch that has been selected for further cell line studies. The statistical analysis was used to support the improved formulation.
- 7 March 2023
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 219-227
Open AccessA STRATEGIC PROCESS DEVELOPMENT AND IN VITRO CYTOTOXICITY ANALYSIS OF PACLITAXEL-LOADED LIPOSOMES
Objective: Liposomes are the controlled-release dosage form that improves the therapeutic efficacy of the drugs, prolongs the duration of action, reduces dosage frequency, and improves patient compliance. Methods: The thin-film hydration method was used to prepare Paclitaxel liposomes. In this process, cholesterol and sodium deoxycholate were used for the formulation, while chloroform and methanol were used as diluents. Percentage (%) drug release study was carried out in phosphate buffer at pH 7.4 in USP apparatus II (Paddle type)Model no VDA-8D, Veego, Mumbai, India. Results: Paclitaxel liposomes of various batches showed a percentage yield ranging from 38 to 84%. It was observed that (Encapsulation efficiency)EE% of Batches B1 to B10 were 0,62.33,59.51,50.21,44.30,82.25,88.95,72.34,77.37 and 70.63 percentage, respectively. Data fitting to the Peppas, Higuchi, 1st-order, and zero-order models was used to examine the optimized liposome (B7) release kinetic mechanism. Data comparison was done using the correlation coefficient (R2). Zero-order had an observed correlation coefficient (R2) of 0.9988, which was greater than that for other models. Therefore, it was clear that the medication was released from the formulation after the zero-order release. Conclusion: The prepared liposomes were subjected to various evaluation parameters like SEM, zeta potential, particle size analysis, drug release study, etc. Data showed that an increased concentration of cholesterol increases the drug release from liposomes. Microscopic images of the B7 batch revealed that liposomes are spherical and have regular surfaces. Formulation B7 shows good results and can be considered an optimized batch that has been selected for further cell line studies. The statistical analysis was used to support the improved formulation.
- Open Access
- 7 November 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 42-50
DETERMINATION OF METFORMIN AND SITAGLIPTIN IN HEALTHY HUMAN VOLUNTEERS' BLOOD PLASMA AND ITS BIOEQUIVALENCE STUDY UNDER FASTING CONDITION
Objective: Metformin hydrochloride and sitagliptin are the oral anti-hyperglycemic medications used to treat type 2 diabetes and are used in combination to treat patients. In this work, we have developed a bioanalytical method for simultaneous estimation of both the drugs form some formulation and subsequently the validation of the developed method metformin and sitagliptin in human plasma. Methods: The stability studies were done as per USFDA and EMA guidelines. The sample extraction approach presented here was a straightforward liquid extraction. The linearity range of metformin was 11.72 ng/ml to 3000 ng/ml, and sitagliptin was 4.68 ng/ml. to 1200 ng/ml. For metformin, the LOD was 1.0 ng/ml, and LLOQ was 11.72 ng/ml. and for sitagliptin, the LOD was 0.75 ng/ml, and LLOQ was 4.68 ng/ml. LC-ESI-MS/MS was used to develop and validate this method using the Phenomenex Kinetex C18 column. Milli-Q water containing 10 mmol Ammonium Acetate (pH =3.6) and Acetonitrile containing 0.1% Formic Acid (pH =2.4) as solvent systems for the estimation of Sitagliptin in a single dose. Metoprolol is used as an Internal Standard. Results: The total chromatographic run time was only 7.0 min, and the elute time of metformin and sitagliptin was 3.94 min and 3.97 min, respectively. Relative Bioavailability was found at 101.14% for Metformin and 96.96% for Sitagliptin. The overall results show that the Cmax, AUC0-t, and AUC0-∞ for metformin and sitagliptin were within the acceptable limit of 80%-125%. Conclusion: This bioanalytical method was successfully applied in the bioequivalence study. The study design was a randomized, open-label, two treatment, two-period, two sequences, single-dose, crossover bioequivalence study under fasting conditions.
- 7 November 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 42-50
Open AccessDETERMINATION OF METFORMIN AND SITAGLIPTIN IN HEALTHY HUMAN VOLUNTEERS' BLOOD PLASMA AND ITS BIOEQUIVALENCE STUDY UNDER FASTING CONDITION
Objective: Metformin hydrochloride and sitagliptin are the oral anti-hyperglycemic medications used to treat type 2 diabetes and are used in combination to treat patients. In this work, we have developed a bioanalytical method for simultaneous estimation of both the drugs form some formulation and subsequently the validation of the developed method metformin and sitagliptin in human plasma. Methods: The stability studies were done as per USFDA and EMA guidelines. The sample extraction approach presented here was a straightforward liquid extraction. The linearity range of metformin was 11.72 ng/ml to 3000 ng/ml, and sitagliptin was 4.68 ng/ml. to 1200 ng/ml. For metformin, the LOD was 1.0 ng/ml, and LLOQ was 11.72 ng/ml. and for sitagliptin, the LOD was 0.75 ng/ml, and LLOQ was 4.68 ng/ml. LC-ESI-MS/MS was used to develop and validate this method using the Phenomenex Kinetex C18 column. Milli-Q water containing 10 mmol Ammonium Acetate (pH =3.6) and Acetonitrile containing 0.1% Formic Acid (pH =2.4) as solvent systems for the estimation of Sitagliptin in a single dose. Metoprolol is used as an Internal Standard. Results: The total chromatographic run time was only 7.0 min, and the elute time of metformin and sitagliptin was 3.94 min and 3.97 min, respectively. Relative Bioavailability was found at 101.14% for Metformin and 96.96% for Sitagliptin. The overall results show that the Cmax, AUC0-t, and AUC0-∞ for metformin and sitagliptin were within the acceptable limit of 80%-125%. Conclusion: This bioanalytical method was successfully applied in the bioequivalence study. The study design was a randomized, open-label, two treatment, two-period, two sequences, single-dose, crossover bioequivalence study under fasting conditions.